drugset
Drugs / Human Placental Derived Stem Cell
last change Sep 2022 re-read 3 minutes ago

Human Placental Derived Stem Cell

Cell therapy

Developed for
acute lymphoblastic leukemia · acute myeloid leukemia · adrenoleukodystrophy · Diamond-Blackfan anemia · fucosidosis · Gaucher disease · juvenile neuronal ceroid lipofuscinosis · Krabbe disease
+7 more · metachromatic leukodystrophy · mucopolysaccharidosis type 1 · mucopolysaccharidosis type 6 · myelodysplastic syndrome · Niemann-Pick disease · thrombocytopenia · Wolman disease
Investigated by
New York Medical College

Trials 1

today NCT01586455 · Ph 1
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01586455 Apr 2013 → Jun 2020 Diamond-Blackfan anemia, Gaucher disease, Krabbe disease, Niemann-Pick disease +11 New York Medical College Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Human Placental Derived Stem Cell ClinicalTrials.gov intervention name — accepted as the source's own label NCT01586455 ↗
Modality Cell therapy “human placental-derived stem cells (HPDSC)” NCT01586455 ↗